Clinical circumstances Recommendations for use of sentinel node biopsy Level of evidence T1 or T2 tumors Acceptable Good T3 or T4 tumors Not recommended Insufficient Multicentric tumors Acceptable Limited Inflammatory…
Darius S. Francescatti and Melvin J. Silverstein (eds.)Breast Cancer2014A New Era in Management10.1007/978-1-4614-8063-1_16© Springer Science+Business Media New York 2014 16. The Surgical Management of Invasive Breast Cancer Beth C. Freedman1, Alyssa Gillego2 and Susan K. Boolbol3 (1) Department of Breast…
Trial Year Disease N Treatment Complete ablation Complications Jeffrey et al. [15] 1999 T3–T4 breast cancer or tumors >5 cm 5 Intraoperative RFA—mastectomy 80 % None Izzo et al. [16]…
Fig. 7.1 (a) First stereotactic table imported into the United States in 1985. (b) The module on which the biopsy needle was positioned and manually operated. (c) Stereotactic breast biopsy…
Figure 15.1 Peripheral blood smear in patient 1 shows dysplastic granulocytes, with hypogranular cytoplasm and megaloblastoid chromatin. Two myelocytes (top) are part of a significant left shift. A segmented neutrophil…
Figure 12.1 Darier’s sign. Blood tests carried out show a normal full blood count, liver function tests, and bone profile (calcium and vitamin D level). Is a skin biopsy necessary…
JAK1/2 inhibitor therapy has potential to improve the pre-HCT performance status by effective control of MF-related symptom burdenSeveral transplant studies have shown the relationship with, or better performance status with,…
Figure 14.1 The spectrum of bone marrow failure disorders and other myeloid neoplasms. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MPN, myeloproliferative neoplasm; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic…
Figure 16.1 Diagnostic algorithm for pediatric thrombocytosis. TIBC, total iron-binding capacity; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CBC, complete blood count; MPN, myeloproliferative neoplasm; CML, chronic myeloid leukemia. Secondary…
Figure 21.1 Clinical and pathogenetic changes occurring during myeloproliferative disorder progression. MPN, myeloproliferative neoplasm; MPN-BP, MPN blast phase; ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polcythemia vera; MF, myelofibrosis; LDH,…
